REUTERS: AstraZeneca Plc and Merck & Co Inc said on Monday their drug to treat a form of ovarian cancer improved progression-free survival in patients tested in a late-stage study.
The study tested Lynparza in patients as an add-on to an already existing standard of care, bevacizumab, and was compared to a group of patients given bevacizumab alone.Lynparza added to bevacizumab reduced the risk of disease progression or death by 41per cent in the overall trial population.
Source: Healthcare Press (healthcarepress.net)
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Separate GSK, AstraZeneca trial results may widen ovarian cancer drug useGlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Bristol-Myers immunotherapy combo outperforms chemo in lung cancer survival: studyAbout 40per cent of patients who received a combination of Bristol-Myers Squibb Co's immuno-oncology drugs Opdivo and Yervoy as an initial ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Novartis says Kisqali boosts survival in breast cancer patientsNovartis said on Sunday that Kisqali helped women with advanced breast cancer after menopause live longer, adding to data the Swiss company hopes ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
China's factory activity edges up in SeptemberChina's manufacturing sector showed unexpected signs of improvement with two indexes showing Monday that manufacturing activity edged up in ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Why can’t we stop pancreatic cancer?
Source: TODAYonline - 🏆 1. / 99 Read more »
More protection needed against cancer-causing cigarette smokeThe Health Sciences Authority’s recent decision to stop the sale and supply of eight heartburn medicines because they contain cancer-causing impurities would worry many people, since these are widely used medicines for a common condition.
Source: TODAYonline - 🏆 1. / 99 Read more »